By Turna Ray
Although big pharma has historically expressed a healthy dose of skepticism about the economic value of pharmacogenomic strategies, a recent study funded by the pharmaceutical industry suggests that pharmacogenomics has the potential to increase investment in R&D and yield greater financial returns for drug companies.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
